Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed

Area of Science:

• Oncology
• Pharmacology

Background:

• Platinum-based chemotherapy offers limited survival benefits for advanced non-small cell lung cancer (NSCLC).
• Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, implicated in tumor growth.
• Gefitinib has received marketing authorization in some regions but is used on a named-patient basis elsewhere.

Purpose of the Study:

• To evaluate the efficacy and safety of gefitinib monotherapy in patients with advanced NSCLC who failed prior chemotherapy.
• To assess gefitinib's impact on survival and symptomatic improvement.
• To determine if gefitinib enhances first-line platinum-based chemotherapy efficacy.

Main Methods:

• Two double-blind, dose-finding studies compared gefitinib 250 mg/day and 500 mg/day in pre-treated NSCLC patients.
• Two large double-blind trials evaluated gefitinib in combination with first-line platinum chemotherapy.
• Adverse events and drug interactions were monitored.

Main Results:

• Gefitinib monotherapy showed a median survival of 6 months and symptomatic improvement in some patients, but study limitations exist.
• Gefitinib did not improve efficacy when added to first-line platinum chemotherapy.
• Common adverse events included gastrointestinal issues and skin reactions; 15% discontinued treatment.
• Interstitial pneumonitis occurred in 1% of patients, with a 33% mortality rate.
• Gefitinib is metabolized by CYP3A4, indicating a high potential for drug interactions.

Conclusions:

• Gefitinib monotherapy offers limited benefits in pre-treated NSCLC patients, with notable adverse events and potential drug interactions.
• Gefitinib does not enhance the efficacy of first-line platinum-based chemotherapy for NSCLC.
• Further comprehensive evaluation of gefitinib is required to establish its clinical benefit and justify marketing authorization for NSCLC.